Boston Scientific Corp. (BSX) faces a significant analyst price-target reduction from Oppenheimer, which lowered its target to USD 65.00 from USD 85.00 on September 21, 2026. This downgrade follows an August cybersecurity incident that disrupted manufacturing and shipments, with the company stating in a September 8 filing that the event is likely to materially impact third-quarter and full-year 2026 results. Despite the operational setbacks, Boston Scientific reported strong second-quarter financial performance with net sales rising 7.5% to USD 5.442 billion. Adjusted earnings per share reached USD 0.86, surpassing the company's guidance range of USD 0.82 to USD 0.84. The Cardiovascular business drove growth with USD 3.624 billion in sales, while MedSurg sales increased by 5.9% to USD 1.818 billion. Analyst sentiment remains mixed but generally positive regarding the long-term outlook, with an average 12-month price objective of USD 70.19 across thirty-one research firms. While Wells Fargo also cut its target slightly, the majority of analysts maintain buy ratings. The company expects to provide updated operational and financial guidance on October 28, 2026, following discussions of third-quarter results. Manufacturing has resumed across most global facilities, though major distribution centers are processing orders at normal or above-normal levels. The incident identified unauthorized activity on August 25, 2026, affecting order processing and customer shipments. With a market capitalization of USD 65.2 billion, the stock continues to trade within its 52-week range as investors weigh the cybersecurity fallout against robust quarterly revenue growth.